Loading...
Development of 5-hydroxypyrazole derivatives as reversible inhibitors of lysine specific demethylase 1.
Mould, Daniel P Bremberg, U Jordan, Allan M Geitmann, M Maiques-Diaz, Alba McGonagle, Alison E Small, Helen F Somervaille, Tim C P Ogilvie, Donald J
Mould, Daniel P
Bremberg, U
Jordan, Allan M
Geitmann, M
Maiques-Diaz, Alba
McGonagle, Alison E
Small, Helen F
Somervaille, Tim C P
Ogilvie, Donald J
Citations
Altmetric:
Abstract
A series of reversible inhibitors of lysine specific demethylase 1 (LSD1) with a 5-hydroxypyrazole scaffold have been developed from compound 7, which was identified from the patent literature. Surface plasmon resonance (SPR) and biochemical analysis showed it to be a reversible LSD1 inhibitor with an IC50 value of 0.23µM. Optimisation of this compound by rational design afforded compounds with Kd values of <10nM. In human THP-1 cells, these compounds were found to upregulate the expression of the surrogate cellular biomarker CD86. Compound 11p was found to have moderate oral bioavailability in mice suggesting its potential for use as an in vivo tool compound.
Description
Date
2017-05-08
Publisher
Collections
Keywords
Type
Article
Citation
Development of 5-hydroxypyrazole derivatives as reversible inhibitors of lysine specific demethylase 1. 2017 Bioorg. Med. Chem. Lett.